GeoVax Labs Inc.’s (OTCQB: GOVX) stock value and volume continued to surge Oct. 22 three weeks after the Atlanta-based bio-tech company said that it is developing two Ebola vaccines.
On Oct. 22, GOVX’s share price closed at 33 cents, up 6 cents, or 22.22% from its closing price of 27 cents the previous day. However, its stock volume was low, with just 186.160 shares changing hands, substantially less its 30-day average volume of 263,726 shares.
Two Ebola Vaccines Being Developed
GeoVax announced Oct. 2 that it is developing two Ebola vaccines, GOVX-E301 and GOVX-E302.
Both are vaccines designed to produce non-infectious virus-like particles displaying the Ebola virus glycoprotein. GOVX-E301 is being developed as a single-dose vaccine for epidemic response against the ZEBOV strain of Ebola, the virus responsible for the current outbreak.
GOVX-E302 is being developed for routine immunization and is designed to protect against all three versions of Ebola known to be lethal in humans.
With a fast-moving epidemic threatening large populations in Africa, and no proven therapy available, an effective vaccine against Ebola is desperately needed. According to the company, the GeoVax recombinant MVA platform is uniquely suited to deliver a potent and safe vaccine capable of protecting people against Ebola hemorrhagic fever.
GeoVax's Ebola vaccine development efforts will be facilitated by the company's proximity to, and collaboration with, the CDC in Atlanta and its experts and Biosafety Level 4 facilities for testing vaccine responses against lethal hemorrhagic viruses.
Since 1976, when Ebola was first discovered, over 20 outbreaks have occurred. Ebola naturally infects animals including bats, creating a reservoir of Ebola that, like rabies, cannot be eradicated completely. An effective vaccine against Ebola would dramatically reduce the epidemic spread of infections as well as the transmission of Ebola from its natural animal hosts to humans.
Find out what could be the best investor’s move when it comes to GOVX by getting the complete report here or by cutting and pasting the following link in your Web browser:
Plandai Biotechnology Begins to Lay Out Product Marketing Plans
Plandai Biotechnology Inc. (OTCQB: PLPL), a company that develops heath products from cannabis plant extracts, announced Oct. 17 that it has begun to lay out its initial plan this week explaining just how the company will get its first product, a green tea extract, into the hands of distributors once production begins at its facility in South Africa by the end of 2014.
The company announced that it will first ship samples of its Phytofare(TM) Catechin Complex, to a list of potential customers worldwide. Plandai's samples will be part of a package of information that will include the green tea product, brochures, a product profile, and most importantly, the preliminary results from a recent clinical trial, safety data, and stability data (shelf life).
This all sounds good, but it remains to be seen if Plandai’s plans ever come to fruition.
On Oct. 22, the share value of PLPL closed at 40 cents, down 3 cents from the previous day’s close of 43 cents, on volume of 291,634 shares.
Find out what could be the best investor’s move when it comes to PLPL by getting the complete report here or by cutting and pasting the following link in your Web browser:
International Stem Cell Corp. Share Value Rises 22.28%
International Stem Cell Corp.'s (OTCQB: ISCO) share volume skyrocketed Oct. 22, with 2.6 million shares changing hands, more than 5 times its 30-day average volume of 502,860 shares.
Meanwhile, ISCO’s share price closed at 10 cents, up 2 cent, or 22.28%, from the previous day’s closing price of 9 cents.
The surge in volume and share value is being fueled in part by the California-based biotech’s announcement it has entered into definitive agreements with a large institutional healthcare investor and management for the private placement of $2.5 million of the company's convertible preferred stock and common stock purchase warrants purchasing up to an additional $7.5 million of the company's common stock.
The closing of the offering is expected to occur on or about October 13, 2014, subject to satisfaction of customary closing conditions set forth in the purchase agreement.
Find out what could be the best investor’s move when it comes to ISCO by getting the complete report here or by cutting and pasting the following link in your Web browser:
Soligenix Inc. Share Value Is Flat amid Soaring Volume
Soligenix Inc.'s (OTCQB: SNGX) share value increased 1% Oct. 22, with SNGX shares closing at $2.03, up 2 cents from previous day‘s close of $2.01.
However, its stock volume soared with 101,164 shares changing hands, more than twice its 30-day average volume of 37,756 shares.
The uptick is being fueled in part by the Princeton, NJ.-based biopharma’s recent announcement that it has won a contract valued at up to $24.7 million inclusive of options by the U.S. Department of Health and Human Service's National Institutes of Health.
The contract contains a 16 month base period providing financial support of approximately $5.8 million, followed by several contract options that would extend the contract award for up to six years.
If all contract options are exercised, the total award will support the preclinical, manufacturing and clinical development activities necessary to get approval with the FDA for its new drug that treats acute radiation symptoms.
Find out what could be the best investor’s move when it comes to SNGX by getting the complete report here, or by cutting and pasting the following link in your Web browser:
http://www.sixfigurestockpicks.com
ABOUT US:
www.sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
www.sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
www.sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the www.sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: www.sixfigurestockpicks.com
Disclosure
www.sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.